Home / Business and Economy / AtaiBeckley Director Sells $496K in Stock
AtaiBeckley Director Sells $496K in Stock
10 Jul
Summary
- Director sold 100,000 shares for $496,000 on July 7, 2026.
- The sale was part of a pre-set Rule 10b5-1 trading plan.
- AtaiBeckley develops treatments for mental health conditions.
On July 7, 2026, Robert Hershberg, a director at AtaiBeckley Inc., sold 100,000 shares of common stock, generating $496,000. This transaction involved the exercise of options with a $1.35 strike price, converted into stock and then sold at an average price of $4.96 per share. The sale occurred automatically as per a Rule 10b5-1 trading plan initiated on April 7, 2026, ensuring no insider timing based on non-public information. Despite this sale, Hershberg retains 100,000 direct shares and 404,869 derivative securities.
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for mental health disorders. Its pipeline includes BPL-003, an intranasal mebufotenin benzoate salt formulation undergoing Phase 2a and 2b trials. The company operates globally, with research and development in the United States, Germany, and Canada, targeting unmet needs in psychiatric care. The company's stock had seen an 89% return in the year preceding the transaction.
